ANTIDIABETIC

Orbit’sANTIDIABETICS

Portfolio

Drugs used in diabetes treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of Insulin, exenatide, liraglutide and pramlintide, all are adminis-tered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.

Below listed the Orbit’s Portfolio

NAME

Metformin Tablets BP 500 mg

Metformin Tablets BP 850 mg

Metformin Sustained Tablets BP 500 mg

Metformin Hydrochloride Sustained Release Tablets 1000 mg

Glibenclamide Tablets BP 5 mg

Glibenclamide With Metformin Hydrochloride Tablets 5 mg + 500 mg

Glimepiridine Tablets 1 mg

Glimepiridine Tablets 2 mg

Glimepiride and Extended Release Metformin Hydrochloride Tablets 1 mg + 500 mg

Glimepiride and Extended Release Metformin Hydrochloride Tablets 2 mg + 500 mg

Glipizide tablets BP 5mg

Acarbose 25/50 mg

Gliclazide 80mg

Metformin 500mg + Gliclazide 80mg

Indapamide ip 1.5mg (SR)

Metformin 500mg + Glimepiride 2mg + Pioglitazone 15mg

Metformin HCL 500/1000MG( SR)

Metformin SR 500mg + Glimepiride 1/2 mg

Metformin 500mg + Glimepiride 1mg + Pioglitazone 15mg

Metformin 1000mg (SR)+ Glimepiride 1mg + Pioglitazone 15mg

Metformin 1000mg (SR)+ Glimepiride 2mg + Pioglitazone 15mg

Metformin SR 500mg + Pioglitazone 15mg

Metformin SR 500mg + Voglibose 0.2/0.3mg

Metformin 500/1000mg (SR) + Glimpride 1/2mg

ANTIDIABETIC

ABOUT ORBIT

Orbit LifeSciences - Pioneer In Delivering Health Outcomes

The information in this document is the property of Orbit or its licensors and is protected by copyright and other intellectual property laws. The information in this document is confidential and may be legally privileged or exempt from disclosure under applicable law and shall not attach any liability on the originator. It is intended solely for the addressee. This document shall and will neither be copied, distributed nor have the contents disseminated to anyone else aside from the addressee, without the prior approval of Alhev Access to this document by anyone else is unauthorized. If you are not the intended recipient, or a person responsible for delivery of this document to an intended recipient, any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it, is prohibited and may be unlawful. Also, you may not copy, print, store, deliver, disseminate or distribute this document to anyone. If you have received this document in error or in such a case, as described herein, please destroy this document and any copies immediately and notify the sender by email at info@orbit.com

When addressed to our clients, any opinions or advice contained in this document are subject to the terms and conditions expressed in the governing Orbit - client engagement letter. While the Orbit team tries its best to keep the information up-to-date in line with the evolving trends, Orbit assumes no responsibility for the validity and correctness of the information provided.

Orbit Lifesciences is on a mission to deliver quality health through its innovative, evolving and growing product portfolio. Launched in 2004, Orbit is a part of Orbit Group.

With a strong focus on innovation, speed of execution & extensive networking Today, orbit Lifescience is reckoned as one of the fastest growing, multi-faceted progressive professional organization in building and delivering mutually beneficial business propositions ranging from In-licensing, Out-licensing and Exports of Finished Formulations.

This is Orbit Proprietary Material.